BMS-986249 is a Monoclonal Antibody owned by Bristol-Myers Squibb, and is involved in 1 clinical trial, which is ongoing.

BMS-986249 acts as a CTLA4 antagonist. The drug candidate inactivates the CTLA-4, thereby activating T-cells. This boosts the immune response against the tumor cells. The drug candidate by the stimulation of the immune system against the tumor cells elicits the therapeutic activity for the treatment of the disease.

The revenue for BMS-986249 is expected to reach a total of $217m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the BMS-986249 NPV Report.

BMS-986249 was originated by Bristol-Myers Squibb and CytomX Therapeutics and is currently owned by Bristol-Myers Squibb.

BMS-986249 Overview

BMS-986249 is under development for the treatment of solid tumors and metastatic melanoma, hepatocellular carcinoma, metastatic castration-resistant prostate cancer and metastatic triple-negative breast cancer. The drug candidate targets CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4). The drug candidate is designed using the Probody platform. It is a probody of ipilimumab. Probodies are fully recombinant, masked antibodies that remain inert in healthy tissue but are activated specifically in the disease microenvironment.

Bristol-Myers Squibb Overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

The company reported revenues of (US Dollars) US$46,385 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. The operating profit of the company was US$8,615 million in FY2021, compared to an operating loss of US$6,847 million in FY2020. The net profit of the company was US$6,994 million in FY2021, compared to a net loss of US$9,015 million in FY2020. The company reported revenues of US$11,218 million for the third quarter ended September 2022, a decrease of 5.6% over the previous quarter.

Quick View – BMS-986249

Report Segments
  • Innovator
Drug Name
  • BMS-986249
Administration Pathway
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.